HighTower Advisors
GLUE icon

HighTower Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

HighTower Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$371K Buy
+15,311
New +$289K ﹤0.01% 3023

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HighTower Advisors's GLUE Position: Q2 2026 in Review

HighTower Advisors opened a new position in Monte Rosa Therapeutics (GLUE) in Q2 2026: 15,311 shares worth $371K. The stake represents ﹤0.01% of the portfolio and ranks #3023 among its holdings.

193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • HighTower Advisors held 15,311 shares of Monte Rosa Therapeutics worth $371K as of Q2 2026.
  • Monte Rosa Therapeutics was a new HighTower Advisors position in Q2 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3023 holding.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.